Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.42 |
| ▸ | FEN1 | P39748 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621373 | 0.83 | ALDH1A1 (0.67) | ALDH1A1ALOX5APFEN1TSHRCYP1A2 | |
| SCHEMBL29689413 | 0.82 | SLC40A1 (0.51) | ALDH1A1ALOX5APFEN1TSHRCYP1A2 | |
| SCHEMBL28712389 | 0.82 | PTGES2 (0.56) | PTGES2ALDH1A1AKR1B1KAT6ASGK1 | |
| SCHEMBL23962786 | 0.81 | HTR6 (0.44) | PTGES2ALDH1A1ALOX5APFEN1TSHR | |
| SCHEMBL16002844 | 0.81 | PTGES2 (0.56) | PTGES2ALDH1A1ALOX5APFEN1KAT6A | |
| SCHEMBL24429391 | 0.81 | NSD2 (0.51) | PTGES2ALDH1A1ALOX5APFEN1LMNA | |
| SCHEMBL5556357 | 0.80 | PTGES2 (0.58) | PTGES2ALDH1A1AKR1B1KAT6ASGK1 | |
| SCHEMBL26426122 | 0.79 | ALDH1A1 (0.42) | PTGES2ALDH1A1ALOX5APFEN1TSHR | |
| SCHEMBL15924548 | 0.77 | FEN1 (0.54) | ALDH1A1ALOX5APFEN1CYP1A2 | |
| SCHEMBL15116336 | 0.77 | PKM (0.49) | ALDH1A1KAT6ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019025156-A1 | SUBSTITUTED PYRROLIDINONES, SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | PTGES2 642/4885ALDH1A1 2078/4885ALOX5AP 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.